Although the overall mutational burden in neuroblastoma is very low compared to other cancer types (Schramm et al., 2015), high-risk disease is often characterized by amplification of the oncogenic driver MYCN (Schwab et al., 1983). The gene discussed is MYCN; the disease is cancer.